+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 55Years - 90Years
All Genders
ID06808984

Evaluation of BMS-986368 for Agitation in Alzheimers Disease A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

Led by Celgene · Updated on 2026-10-06

120

Participants Needed

77

Research Sites

6 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating BMS-986368, a FAAHMAGL inhibitor, for its effects on agitation in people with Alzheimers disease. This Phase 2, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, and tolerability of this oral medication in participants aged 55 to 90 years who meet specific diagnostic and agitation criteria. Participants will be randomly assigned to one of three groups receiving either one of two doses of BMS-986368 or a placebo. The study medication is given orally on specified days during an 8-week treatment period. The trial includes a triple-blind design to ensure unbiased evaluation of outcomes. During the study, participants will be assessed for changes in agitation using tools like the Cohen-Mansfield Agitation Inventory CMAI and other behavioral scales up to Week 8. Safety will be monitored through adverse event tracking and laboratory tests up to 28 days after the last dose. Plasma levels of the study drug will be measured up to Week 14. The total participation lasts through the treatment and follow-up periods as defined by the study schedule.

CONDITIONS

Brief Title

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here